will put Jerry Woods in jail, **Liers are thieves
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference
ANAVEX®2-73 Shown to have Neurorestorative Effects in a Model for Experimental Parkinsonism
NEW YORK, October 30, 2017 - Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced additional data for ANAVEX®2-73 in a model for experimental parkinsonism. The data will be shown today at the Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference taking place at Convene Midtown East, New York City in a poster titled, “ANAVEX2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism.”
The study’s principle investigators, Veronica Francardo, PhD and Angela Cenci, MD, PhD, Professor of Experimental Medical Research at Lund University, Sweden, stated, “These new results indicate that ANAVEX2-73 has robust neurorestorative effects on the nigrostriatal dopaminergic pathway in all doses tested. The encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer’s disease trial, support the notion that ANAVEX2-73 is a promising clinical candidate drug for Parkinson’s disease.”
It was previously shown that ANAVEX2-73 significantly promotes recovery of motor functions (p<0.05), induces higher levels of striatal dopamine fibers (p<0.05) and reduces microglial activation (p<0.05) in a mouse model of nigrostriatal dopaminergic degeneration relevant to Parkinson's disease.
A consistent abnormality in Parkinson's disease is degeneration of dopaminergic neurons in the substantia nigra, leading to a reduction of dopamine axon fibers and dopamine levels in the striatum. As tyrosine hydroxylase (TH) catalyzes the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine, tyrosine hydroxylase-deficiency levels are correlated with the severity of parkinson-like motor deficits.
The additional data reveals that ANAVEX2-73 not only seems to have a wide dose-response profile but also activates neuroplasticity mechanisms and exerts noticeable neurorestorative effects on striatal dopamine axon fibers. This was confirmed by expression of a marker of axonal regeneration in the striatum, Growth Associated Protein 43 (GAP43), being co-localized with TH, which was only found in the ANAVEX2-73-treated animal cohorts but not in the control cohort.
Further analyses are ongoing in order to better understand the underlying mechanisms that contribute to the neurorestorative properties of ANAVEX2-73.
The study is supported by The Michael J. Fox Foundation for Parkinson’s Research.
“These findings are very encouraging and support our strategy to initiate a randomized and placebo controlled phase 2 study in Parkinson's disease with ANAVEX2-73,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest non-profit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges ground breaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors & Media:
Clayton Robertson
The Trout Group
crobertson@troutgroup.com
The additional data reveals that ANAVEX2-73 not only seems to have a wide dose-response profile but also activates neuroplasticity mechanisms and exerts noticeable neurorestorative effects on striatal dopamine axon fibers. This was confirmed by expression of a marker of axonal regeneration in the striatum, Growth Associated Protein 43 (GAP43), being co-localized with TH, which was only found in the ANAVEX2-73-treated animal cohorts but not in the control cohort.
It was previously shown that ANAVEX2-73 significantly promotes recovery of motor functions (p<0.05), induces higher levels of striatal dopamine fibers (p<0.05) and reduces microglial activation (p<0.05) in a mouse model of nigrostriatal dopaminergic degeneration relevant to Parkinson's disease.
“These new results indicate that ANAVEX2-73 has robust neurorestorative effects on the nigrostriatal dopaminergic pathway in all doses tested. The encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer’s disease trial, support the notion that ANAVEX2-73 is a promising clinical candidate drug for Parkinson’s disease.”
is your number $11.86 ??????????
Money and Banking Edition Tuesday, October 31, 2017
U.S. Banks Closing and Consolidating Branches, But Still Growing Deposits
By Remi Lukosiunas, Financial Analyst
Remi Lukosiunas
As you drive down the street, you often see different banks on each side of the road — and sometimes right next to each other. You go a few miles further down the road and once again, buildings with the same names pop up.
But the data shows that, in fact, more and more bank branches are disappearing. The banks themselves aren’t going anywhere … but the numbers of branch locations they operate have been decreasing over time and continue to do so.
In the past five years, the total number of U.S. bank branches has dropped 8.2%. There were 88,863 as of June 30, down from 96,850 in 2012.
Don’t get me wrong, it’s still very convenient and easy to access a bank branch today. But compared to the prior years, there are a lot less of them now.
With technology and mobile applications taking over our lives, the brick-and-mortar branches are becoming less popular, especially with the younger generation. Mobile check deposits, email money transfers, and tons of other services are now right at your fingertips, eliminating the need to wait in line — or even to get out of your office chair!
Of course, some financial matters like accessing your safety deposit box will require you to go see someone at the branch. But most day-to-day financial needs can be met using a computer, a tablet, or a cell phone.
Although numbers are down, some states still have a large physical bank presence. California, Texas, and Florida are the top three states with the most bank branches: 6,840, 6,487, and 5,111 branches, respectively. Still, all top ten states have seen a decline over the last five years, as you can see in this table.
Top 10 States with Most Bank Branches
You might think that with fewer physical branches, banks would see a decrease in deposits. But it’s quite the opposite.
In Q2 2017, the banking industry reported $11.6 trillion in domestic deposits. This is up 34.6% over a nearly five-year period, and 1.6% higher than the year-end 2016 figure.
Some of the largest banks grew their deposits by double digits over the last five years, while simultaneously reducing the number of branches they operate.
Top 5 Largest Domestic Deposit Holders
Bank of America, NA (Rated “B-”), the largest domestic deposit holder, had $1.3 trillion in deposits as of Q2. That was up 21.5% since 2012, despite a branch count drop of 13.1%. Among the top five deposit banks, JPMorgan Chase Bank, NA (Rated “B”) grew its deposits the most, 40.4%, over nearly a five-year period and reduced its branches by 7%. U.S. Bank, NA (Rated “B-”) was the only one of the five with a slight increase in branch numbers since 2012.
FREE REPORT by Dr. Martin Weiss reveals how you can build four great fortunes in 2017-2022.
The bottom line is that banks have grown their deposits tremendously while consolidating, or entirely eliminating, some of their physical properties. This way, they can reduce the cost of operating branches and make technological investments instead.
A mobile phone application that is easy to use and always works will result in countless happy customers who will be thankful for not standing in line to deposit a check or to make a transfer. Online banking has taken over and will continue to expand, but it’s unlikely that it will make brick-and-mortar locations completely go away.
Regardless of who your bank is, or how you prefer to handle your transactions, be sure to follow the safety of your institution on the Weiss Ratings website.
Think Safety,
Remi Lukosiunas
So you are saying they are pulling the divvy out early in effect ?
FC stock just plunged, will the lost gain be stop?
Get your FDIC buddies to buy you another case of boos that will hold you for a while!
You an also add in Factoring the money due.... to create cash flow and pay the bills!
Cheds it all ready broke down, check where you pined your line!
It's my believe that when a Drug company has a drug that will cure Cancer and MS and Baldness all long with a half dozen other diseases, they will do there best to tweak the formula for each disease so they can sell multiple cures and create multiple income streams.
thanks
It is interesting that if you take the 800K shares times $400 you get $320,000,000 Div by 29.4 million shares of UWB you get $10.88 per share.????? That is about HALF of what we should get.
I doubt that , but it tells me that they have FREE CASH FLOW.
I may be wrong BUT , I have all ways been under the understanding that to buy or merge with another company into a public company the bought company must be AUDITED and in some cases both companies are audited, if it is a MERGE both companies must be AUDITED And that may not be the same if it is a assets purchase.
THIS is not the end....third quarter of 2017 was $67.1 million, or $5.58 per share,
compared to $51.4 million, or $4.28 per share, for the corresponding period of 2016, and $134.7 million, or $11.21 per share, for the second quarter of 2017, according to Frank B. Holding, Jr., chairman of the board.
BancShares’ current quarter results generated an annualized return on average assets of 0.77 percent and an annualized return on average equity of 8.10 percent,
compared to respective returns of 0.63 percent and 6.69 percent for the third quarter of 2016, and 1.58 percent and 17.10 percent for the second quarter of 2017.
AND THE NEWS IS....................>>
>>>
FCNCA News: Current Report Filing (8-k) 10/26/2017 02:35:15 PM
FCNCA News: First Citizens BancShares Declares Dividend 10/25/2017 04:06:00 PM
FCNCA News: First Citizens BancShares Reports Earnings for Third Quarter 2017 10/25/2017 04:05:00 PM
FCNCA News: Current Report Filing (8-k) 10/25/2017 03:58:36 PM
FCNCA News: Third Annual First Citizens Bank Small Business Forecast Shows U.S. Small Business Owners Plan to Grow, Millennials Optimisti...
I see NO APPARENT RELEVANCE....
Did your mosquito wake up the next morning and have a hangover? Like I am having now after reading this board and not being able to hear the CC at all but gleaning info off the post on this board not knowing what to do. So as a BVTK long holder
Do I SELL or HOLD, I have seen no clear cut info to give a direction, so the only thing I can do is toss a Coin up!
Not WORKING ON MY END it is garbaled....reproduce (a message, sound, or transmission) in a confused and distorted way.
"the connection was awful and kept garbling his voice"
Participants may access the call by dialing (605) 472-5254 and providing access code 908279 when prompted.
Conference Call [ CC ]
AUSTIN, Texas – Bravatek Solutions, Inc. (OTCPink: BVTK, “Bravatek” or the “Company”) announces that it will hold a conference call for shareholders and interested investors on Wednesday, October 25, 2017 at 4:15pm Eastern Daylight Time. During the call, Bravatek representatives will discuss the Company’s recent initiatives and announcements regarding its suite of engineering, installation and security management solutions to industry and government, as well as entertain questions from participants.
Participants may access the call by dialing (605) 472-5254 and providing access code 908279 when prompted.
This should be Tom's next acquisition.........
https://ih.advfn.com/p.php?pid=nmona&article=75926496
"10/27/2017 will live in infamy"....... Where did this come from???
Yes, and we are all most there!
I think we can add Tire companies and Repair garages even Homeowners insurances.
crude.... I think we will see a spin off in our future.
also tracking bvtkxx and abhixx, watch for cc soon , its going to be a good year.
What do you think will happen when Stephen starts to sell the Save Driving APP to all of the Auto Insurance Companies and they condition your insurance rate on having the App installed.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=134507616
I don't think Bill wants to take care of his shareholders, I am still stuck with Thousands of Dollars in 144 shares from the begging of CCOP. I hope you do well, Good Luck.
You know BOB , what Fred is over gleed about is that and what he is proposing is we accept $4.34 which is only about FIVE YEARS worth OF INTEREST as a pay off! THAT IS ONLY ABOUT $0.868 cents per year
6,600,278 Vol ... 0.0052 X 0.0053 ... 826,817 Bid ... 1,981,656 Ask ... .0052 Last
PS now 53 XX 8 Million
255,000 Vol ... 0.0285 X 0.04 ... 72,000 Bid ... 20,000 Ask .04 Last
Now 1,100,000 @.0051
Shares are on the move before the market is open 350000 pre market all ready AT .0051
Facts are verifiable, show me your FACTS ................>
FACTS ARE VERIFIABLE !!!!
.
110,080,764 Vol ... 0.0054 X 0.0055 ... 10,000 Bid ... 1,710,000 Ask ... Hit the ASK, Hit the ASK, Hit the ASK!
Why do I get the feeling that you are still working for the FDIC?
Well I guess that Guy will have to go back to court and refile the appeal.
You know the FDIC is home free if the FC Bank pays the interest and FC gets to drag out the payment over time. And as per, if FC pays part in stock they get a big discount on what they Pay to us stockholders.
That works for me!
Yes, I will be happy to take 5.25% interest on $500,000,000 for the five years that is owed, a lump sum of $4.46 per share and then interest per diem, when a $17 pay off is paid in full and then we will receive no more interest.
But first, Tom has to restore the communication problem caused by the Hurricanes and put new towers up, also on the Islands ASAP.